

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number
WO 2005/074954 A1

(51) International Patent Classification⁷: **A61K 35/78**,
A61P 1/00

(21) International Application Number:
PCT/EP2005/001041

(22) International Filing Date: 2 February 2005 (02.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04002296.4 3 February 2004 (03.02.2004) EP

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KETZIS, Jennifer** [US/CH]; Bollwerkstrasse 46, CH-4102 Binningen (CH).

(74) Agent: **ROTH, Peter, R.**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SIMAROUBA AMARA AND/OR MOMORDICA CHARANTIA EXTRACTS FOR THE TREATMENT OF COCCIDIOSIS IN POULTRY**

(57) Abstract: Described is the use of a coccidiostatically effective amount of *Simarouba amara* either alone or in combination with *Momordica charantia* for the manufacture of a medicament for the therapy of coccidiosis in poultry. Further described is a method for controlling coccidiosis in poultry based on the administering of said medicament. Described is also a poultry feed supplement or medicated poultry feed for the control of coccidiosis in poultry that comprises besides ground dry vegetable- and/or animal-based poultry feed, with or without additives such as proteins, vitamins and minerals, and a coccidiostatically effective amount of *Simarouba amara* dried bark or an extract thereof either alone or in combination with *Momordica charantia* fruit extract. Also described is the production of said medicament and to the use of said active ingredients as an additive to dry or wet poultry food or drinking water for the prophylactic or curative treatment of coccidial infections in poultry. Another described embodiment relates to the management for preventing the development of resistant *Eimeria* strains that cause coccidiosis in poultry comprising rotation of the administration of a coccidiostatically effective amount of *Simarouba amara* dried bark or an extract thereof and of a coccidiostatically effective amount of *Momordica charantia* fruit extract together with one or more with one or more physiologically acceptable carriers.



WO 2005/074954 A1